During this period, the thrombophilia testing was performed, confirming a milder form of hereditary thrombophilia, with heterozygous mutations for plasminogen activator inhibitor-1 (PAI-1) 5G/4G and methylenetetrahydrofolate reductase (MTHFR) C677T along with high activity of coagulation factor VIII (FVIII) 294% (RI: 50-150%). This evidence concerns the gene SERPINE1 and Rare hereditary thrombophilia.